A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy.
epidemiology
genetic analysis
mortality
paraganglioma
pheochromocytoma
surveillance
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
20 Nov 2021
20 Nov 2021
Historique:
received:
30
10
2021
revised:
12
11
2021
accepted:
18
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
No studies have carried out an extensive analysis of the possible association between non-syndromic pheochromocytomas and paragangliomas (PPGLs) and other malignancies. To assess >the risk of additional malignancy in PPGL, we retrospectively evaluated 741 patients with PPGLs followed-up in twelve referral centers in Italy. Incidence of second malignant tumors was compared between this cohort and Italian patients with two subsequent malignancies. Among our patients, 95 (12.8%) developed a second malignant tumor, which were mainly prostate, colorectal and lung/bronchial cancers in males, breast cancer, differentiated thyroid cancer and melanoma in females. The standardized incidence ratio was 9.59 (95% CI 5.46-15.71) in males and 13.21 (95% CI 7.52-21.63) in females. At multivariable analysis, the risk of developing a second malignant tumor increased with age at diagnosis (HR 2.50, 95% CI 1.15-5.44,
Identifiants
pubmed: 34830985
pii: cancers13225831
doi: 10.3390/cancers13225831
pmc: PMC8616182
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : AIRC
ID : IG-2020-ID.24820
Organisme : MIUR
ID : Departments of Excellence 2018-2022
Organisme : Ricerca Locale Università di Torino 2020
ID : RILO 2020
Références
J Cell Biol. 1998 Aug 10;142(3):827-35
pubmed: 9700169
Diagn Pathol. 2019 May 15;14(1):42
pubmed: 31092265
Nat Rev Cancer. 2013 Mar;13(3):153-9
pubmed: 23550303
Am J Hum Genet. 2004 Jan;74(1):153-9
pubmed: 14685938
Nat Rev Cancer. 2014 Feb;14(2):108-19
pubmed: 24442145
Fam Cancer. 2015 Dec;14(4):603-7
pubmed: 26071763
J Med Genet. 2018 Jun;55(6):384-394
pubmed: 29386252
J Endocr Soc. 2017 Oct 23;1(11):1401-1407
pubmed: 29264463
Breast Cancer Res. 2019 Jan 14;21(1):3
pubmed: 30642363
Eur J Endocrinol. 2018 Jan;178(1):R11-R17
pubmed: 28924001
Nature. 2011 Nov 13;480(7375):99-103
pubmed: 22080950
Horm Metab Res. 2019 Jul;51(7):419-436
pubmed: 30273935
Virchows Arch. 2015 Jun;466(6):727-32
pubmed: 25800244
Histopathology. 2018 Jan;72(1):106-116
pubmed: 29239034
Int J Biochem Cell Biol. 2014 Aug;53:514-9
pubmed: 24886695
Mod Pathol. 2015 Jun;28(6):807-21
pubmed: 25720320
EBioMedicine. 2018 Jul;33:88-93
pubmed: 29937070
Endocr Relat Cancer. 2015 Aug;22(4):T105-22
pubmed: 26113600
Eur J Endocrinol. 2016 May;174(5):G1-G10
pubmed: 27048283
Appl Immunohistochem Mol Morphol. 2014 Jan;22(1):31-6
pubmed: 23531856
J Mol Diagn. 2017 Jul;19(4):575-588
pubmed: 28552549
Adv Clin Chem. 2017;80:45-72
pubmed: 28431642
Sci Transl Med. 2014 Dec 24;6(268):268ra177
pubmed: 25540324
Endocr Pathol. 2017 Sep;28(3):213-227
pubmed: 28477311
Fam Cancer. 2014 Sep;13(3):507-11
pubmed: 24781345
Lancet. 2005 Aug 20-26;366(9486):665-75
pubmed: 16112304
Clin Genet. 2017 Dec;92(6):606-615
pubmed: 28300276
Ann N Y Acad Sci. 2006 Aug;1073:444-8
pubmed: 17102113
Nature. 2011 Oct 19;480(7375):94-8
pubmed: 22012259
Endocr Relat Cancer. 2015 Aug;22(4):E5-7
pubmed: 26273100
Int J Mol Sci. 2020 Oct 26;21(21):
pubmed: 33114769
Indian J Med Res. 2011 Jun;133:605-12
pubmed: 21727658
J Clin Endocrinol Metab. 2016 Dec;101(12):4764-4768
pubmed: 27680874
Bratisl Lek Listy. 2019;120(2):119-123
pubmed: 30793615
Endocr Pathol. 2019 Dec;30(4):276-284
pubmed: 31734934